CL2018002932A1 - Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos. - Google Patents

Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos.

Info

Publication number
CL2018002932A1
CL2018002932A1 CL2018002932A CL2018002932A CL2018002932A1 CL 2018002932 A1 CL2018002932 A1 CL 2018002932A1 CL 2018002932 A CL2018002932 A CL 2018002932A CL 2018002932 A CL2018002932 A CL 2018002932A CL 2018002932 A1 CL2018002932 A1 CL 2018002932A1
Authority
CL
Chile
Prior art keywords
compositions
methods
antigens
antibodies
chagas
Prior art date
Application number
CL2018002932A
Other languages
English (en)
Inventor
Mateo Olga Pleguezuelos
Wilson Romero Caparros-Wanderley
Gregory Alan Stoloff
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of CL2018002932A1 publication Critical patent/CL2018002932A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE MEMORIA DESCRIPTIVA DESCRIBE ANTÍGENOS, COMPOSICIONES INMUNOGÉNICAS DE TRYPANOSOMA Y MEDICAMENTOS QUE COMPRENDEN DICHOS ANTÍGENOS DE TRYPANOSOMA, MÉTODOS Y USOS PARA TALES ANTÍGENOS Y COMPOSICIONES INMUNOGÉNICAS DE TRYPANOSOMA PARA TRATAR UNA ENFERMEDAD BASADA EN TRYPANOSOMA.
CL2018002932A 2016-04-14 2018-10-12 Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos. CL2018002932A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662322770P 2016-04-14 2016-04-14

Publications (1)

Publication Number Publication Date
CL2018002932A1 true CL2018002932A1 (es) 2019-02-01

Family

ID=58671580

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018002932A CL2018002932A1 (es) 2016-04-14 2018-10-12 Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos.
CL2021001441A CL2021001441A1 (es) 2016-04-14 2021-06-02 Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos (divisional de la solicitud no. 201802932)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021001441A CL2021001441A1 (es) 2016-04-14 2021-06-02 Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos (divisional de la solicitud no. 201802932)

Country Status (18)

Country Link
US (2) US10973897B2 (es)
EP (1) EP3442569A1 (es)
JP (1) JP2019513797A (es)
KR (1) KR20190039022A (es)
CN (2) CN116059330A (es)
AU (1) AU2017248680A1 (es)
BR (1) BR112018071108A2 (es)
CA (1) CA3020856A1 (es)
CL (2) CL2018002932A1 (es)
CO (1) CO2018012295A2 (es)
CU (1) CU20180127A7 (es)
EC (1) ECSP18079073A (es)
MX (1) MX2018012504A (es)
NI (1) NI201800105A (es)
PE (1) PE20190104A1 (es)
RU (1) RU2018139865A (es)
SG (1) SG11201808915YA (es)
WO (1) WO2017178660A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2594636B (en) 2019-01-07 2023-08-02 Genome Res Ltd Novel trypanosomal vaccine
GB2594637B (en) * 2019-01-07 2023-08-02 Genome Res Ltd Novel trypanosomal vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731370A1 (de) * 1977-07-12 1979-01-25 Behringwerke Ag Chagas impfstoff und verfahren zu dessen herstellung
ES2169995B1 (es) 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
FR2952382B1 (fr) * 2009-11-10 2011-11-25 Univ Victor Segalen Bordeaux 2 Vaccins et diagnostics contre les trypanosomoses animales africaines
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR112015032978B1 (pt) 2013-07-02 2022-08-16 Institut De Recherche Pour Le Développement Método de diagnóstico para a detecção de anticorpos indicativos de leishmania sul americana e kit de diagnóstico para detecção de anticorpos antileishmaniose
US9566320B2 (en) * 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease

Also Published As

Publication number Publication date
KR20190039022A (ko) 2019-04-10
US20170296637A1 (en) 2017-10-19
WO2017178660A9 (en) 2017-12-07
CN109310747B (zh) 2022-11-22
AU2017248680A1 (en) 2018-11-22
EP3442569A1 (en) 2019-02-20
NI201800105A (es) 2019-02-18
JP2019513797A (ja) 2019-05-30
PE20190104A1 (es) 2019-01-15
WO2017178660A1 (en) 2017-10-19
US10973897B2 (en) 2021-04-13
RU2018139865A (ru) 2020-05-14
CN116059330A (zh) 2023-05-05
CU20180127A7 (es) 2019-08-06
CL2021001441A1 (es) 2021-11-19
CO2018012295A2 (es) 2019-04-30
CA3020856A1 (en) 2017-10-19
CN109310747A (zh) 2019-02-05
US20210220453A1 (en) 2021-07-22
ECSP18079073A (es) 2019-02-28
SG11201808915YA (en) 2018-11-29
BR112018071108A2 (pt) 2019-02-26
MX2018012504A (es) 2019-08-29

Similar Documents

Publication Publication Date Title
UY37523A (es) Anticuerpos anti-ox40 y sus usos
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
MX384781B (es) Moleculas de union tri-especificas y metodos de uso de las mismas.
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
DK3408295T5 (da) Farmaceutisk sammensætning, som omfatter bispecifikke antistofkonstruktioner
ECSP17001673A (es) Anticuerpos monoclonales contra el epitope de her2
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
BR112016024856A2 (pt) processo para a produção de microcápsulas que contêm um envoltório feito de poliureia obtido na presença de copolímeros de álcool polivinílico
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
PT3096785T (pt) Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
CO2017003005A2 (es) Anticuerpos anti-mfi2
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PT3528787T (pt) Formulações farmacêuticas e métodos para produzir as mesmas
MX2016008903A (es) Composicion adhesiva fusionada por calor en espuma para unir empaques de envases.
MX2016017025A (es) Formulaciones de proteinas.
MX2017000526A (es) Formulaciones de anticuerpos cristalinos.
BR112017008097A2 (pt) método para tratar condições oculares
CL2018002932A1 (es) Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
MX2020001954A (es) Composiciones para el cuidado bucal y sus usos.
CL2020000793A1 (es) Método para preparar micropartículas según la técnica de doble emulsión
ES1210064Y (es) Cápsula monodosis para biberón